Patheon Announces Date of Third Quarter Fiscal 2012 Financial Results
TORONTO, Sept. 4, 2012 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it will report its third quarter fiscal 2012 financial results on Thursday, September 13, 2012.
In conjunction with its financial results announcement, Patheon will host a conference call Thursday, September 13, 2012 at 8:30 a.m. (EDT). The financial results news release will be issued at approximately 7:00 a.m. (EDT) Thursday, September 13, 2012.
Interested parties are invited to access the conference call, via telephone, in listen-only mode, toll free at 1-888-231-8191 (U.S., including Puerto Rico) and 1-647-427-7450 (Canada and International). Listeners are encouraged to dial in five to fifteen minutes in advance to avoid delays. Slides will also be available for viewing during the call by accessing http://ir.patheon.com/events.cfm
A telephone replay of the conference call will be available between Thursday, September 13, 2012 and Thursday, September 27, 2012 by dialling 1-855-859-2056 (toll free) or 1-403-451-9481, and by entering identification number 19083494, followed by the number key. The conference call will be archived at http://ir.patheon.com/events.cfm.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, soft gel, liquid-filled hard capsules and a variety of modified release technologies.
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. The company's integrated development and manufacturing network of 10 manufacturing facilities, eight development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
SOURCE Patheon Inc.